Venus treatments wins battle in opposition to French pharma agency to revoke Indian patent for intravenous paracetamol, Well being Information, ET HealthWorld

  • Venus remedies wins battle against French pharma firm to revoke Indian patent for intravenous paracetamolChandigarh, seventeenth June: In a historic breakthrough for the Pharmaceutical trade within the nation, Venus Cures Restricted received a 10-year lengthy authorized battle that challenged patent claimed by French pharmaceutical agency SCR Pharmatop for producing the intravenous paracetamol answer in India.

In a call dated 4th June, 2021, the Indian Patent Workplace determined in favour of Venus Cures and upheld its resolution for revocation of the Indian patent on the grounds that the method lacked any ingenious step that made it superior to different present options.

Venus’s opposition was meant to take away any Indian Patent hurdle in manufacturing of Intravenous Paracetamol answer in India. As intravenous paracetamol performs a vital function in managing irritation and fever, therefore the revocation of this patent is an encouraging growth for the healthcare sector within the nation reeling below the present pandemic.

Sharing the event with the important thing stakeholders of the corporate, Saransh Chaudhary, President, World Vital Care, Venus Cures Ltd stated, “We’re dedicated to discovering and creating the most effective options for international well being challenges the most important a part of which is bridging the hole between individuals and sturdy healthcare services. Our endeavor right here was to be sure that vital medication akin to Intravenous Paracetamol is offered in our nation to be manufactured generically and accessible at economical costs for most of the people, notably throughout these tough occasions.”

VRL filed the post-grant opposition in opposition to the SCR Pharmatop’s intravenous paracetamol patent again in 2011 earlier than Indian Patent Workplace on a number of grounds akin to lack of novelty and lack of ingenious steps, amongst others. Through the course of the case, Patent Workplace first revoked the patent in 2018 observing that the claims made by SCR Pharmatop are apparent to an atypical individual expert within the artwork, nonetheless, the corporate moved their plea to Delhi Excessive Court docket and Mental Property Appellate Board (IPAB). IPAB directed the Patent workplace to once more hear the matter and after listening to and written submissions from each the events the Indian Patent Workplace gave its last resolution on 4th June, 2021, sustaining the revocation order of Patent no.238164, dated twenty fourth December 2018.



Source link